Is Anika Therapeutics, Inc. overvalued?

Anika Therapeutics, Inc. (ANIK) looks overvalued — trading about 53% above its fair value.

Overvalued

Price

$21.50

Fair value

$10.12

Current P/E

43.9

Normal P/E

20.7

Market cap

$287.7M

Dividend yield

0.0%

Return on equity

-2.7%

Sector

Healthcare

Fair value compares ANIK's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 11 Aug 2026.

Related stocks